Selected research
Industry Research
Antivirals Industry Research Report 2026
Market perspective
The global Antivirals market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Antivirals is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Antivirals is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Antivirals is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Antivirals include Teva Pharmaceutical Industries, Johnson & Johnson, Merck, Mylan, Gilead Sciences, GSK, AbbVie, F. Hoffmann-La Roche and Dr Reddy’s, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Antivirals market in terms of revenue (US$ million) and, where applicable, sales volume (k tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Antivirals Market by Company
Teva Pharmaceutical Industries
Johnson & Johnson
Merck
Mylan
Gilead Sciences
GSK
AbbVie
F. Hoffmann-La Roche
Dr Reddy’s
Cipla
Bristol-Myers-Squibb
Aurobindo Pharma
Antivirals Segment by Type
Generic
Branded
Antivirals Segment by Application
HIV
Influenza
Hepatitis
HSV
Antivirals Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antivirals market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Antivirals and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antivirals.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Antivirals manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Antivirals by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Antivirals in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Generic
- Branded
Applications
- HIV
- Influenza
- Hepatitis
- HSV
Companies covered
- Teva Pharmaceutical Industries
- Johnson & Johnson
- Merck
- Mylan
- Gilead Sciences
- GSK
- AbbVie
- F. Hoffmann-La Roche
- Dr Reddy’s
- Cipla
- Bristol-Myers-Squibb
- Aurobindo Pharma
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Antivirals Market Size (2021-2032)
- 2.2.2 Global Antivirals Sales (2021-2032)
- 2.2.3 Global Antivirals Market Average Price (2021-2032)
- 2.3 Antivirals by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Generic
- 2.3.3 Branded
- 2.4 Antivirals by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 HIV
- 2.4.3 Influenza
- 2.4.4 Hepatitis
- 2.4.5 HSV
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Antivirals Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Antivirals Sales (k tons) of Manufacturers (2021-2026)
- 3.3 Global Antivirals Revenue of Manufacturers (2021-2026)
- 3.4 Global Antivirals Average Price by Manufacturers (2021-2026)
- 3.5 Global Antivirals Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Antivirals, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Antivirals, Product Type & Application
- 3.8 Global Manufacturers of Antivirals, Established Date
- 3.9 Global Antivirals Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Teva Pharmaceutical Industries
- 4.1.1 Teva Pharmaceutical Industries Company Information
- 4.1.2 Teva Pharmaceutical Industries Business Overview
- 4.1.3 Teva Pharmaceutical Industries Antivirals Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Teva Pharmaceutical Industries Antivirals Product Portfolio
- 4.1.5 Teva Pharmaceutical Industries Recent Developments
- 4.2 Johnson & Johnson
- 4.2.1 Johnson & Johnson Company Information
- 4.2.2 Johnson & Johnson Business Overview
- 4.2.3 Johnson & Johnson Antivirals Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Johnson & Johnson Antivirals Product Portfolio
- 4.2.5 Johnson & Johnson Recent Developments
- 4.3 Merck
- 4.3.1 Merck Company Information
- 4.3.2 Merck Business Overview
- 4.3.3 Merck Antivirals Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Merck Antivirals Product Portfolio
- 4.3.5 Merck Recent Developments
- 4.4 Mylan
- 4.4.1 Mylan Company Information
- 4.4.2 Mylan Business Overview
- 4.4.3 Mylan Antivirals Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Mylan Antivirals Product Portfolio
- 4.4.5 Mylan Recent Developments
- 4.5 Gilead Sciences
- 4.5.1 Gilead Sciences Company Information
- 4.5.2 Gilead Sciences Business Overview
- 4.5.3 Gilead Sciences Antivirals Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Gilead Sciences Antivirals Product Portfolio
- 4.5.5 Gilead Sciences Recent Developments
- 4.6 GSK
- 4.6.1 GSK Company Information
- 4.6.2 GSK Business Overview
- 4.6.3 GSK Antivirals Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 GSK Antivirals Product Portfolio
- 4.6.5 GSK Recent Developments
- 4.7 AbbVie
- 4.7.1 AbbVie Company Information
- 4.7.2 AbbVie Business Overview
- 4.7.3 AbbVie Antivirals Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 AbbVie Antivirals Product Portfolio
- 4.7.5 AbbVie Recent Developments
- 4.8 F. Hoffmann-La Roche
- 4.8.1 F. Hoffmann-La Roche Company Information
- 4.8.2 F. Hoffmann-La Roche Business Overview
- 4.8.3 F. Hoffmann-La Roche Antivirals Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 F. Hoffmann-La Roche Antivirals Product Portfolio
- 4.8.5 F. Hoffmann-La Roche Recent Developments
- 4.9 Dr Reddy’s
- 4.9.1 Dr Reddy’s Company Information
- 4.9.2 Dr Reddy’s Business Overview
- 4.9.3 Dr Reddy’s Antivirals Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Dr Reddy’s Antivirals Product Portfolio
- 4.9.5 Dr Reddy’s Recent Developments
- 4.10 Cipla
- 4.10.1 Cipla Company Information
- 4.10.2 Cipla Business Overview
- 4.10.3 Cipla Antivirals Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Cipla Antivirals Product Portfolio
- 4.10.5 Cipla Recent Developments
- 4.11 Bristol-Myers-Squibb
- 4.11.1 Bristol-Myers-Squibb Company Information
- 4.11.2 Bristol-Myers-Squibb Business Overview
- 4.11.3 Bristol-Myers-Squibb Antivirals Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Bristol-Myers-Squibb Antivirals Product Portfolio
- 4.11.5 Bristol-Myers-Squibb Recent Developments
- 4.12 Aurobindo Pharma
- 4.12.1 Aurobindo Pharma Company Information
- 4.12.2 Aurobindo Pharma Business Overview
- 4.12.3 Aurobindo Pharma Antivirals Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Aurobindo Pharma Antivirals Product Portfolio
- 4.12.5 Aurobindo Pharma Recent Developments
5 Global Antivirals Market Scenario by Region
- 5.1 Global Antivirals Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Antivirals Sales by Region: 2021-2032
- 5.2.1 Global Antivirals Sales by Region: 2021-2026
- 5.2.2 Global Antivirals Sales by Region: 2027-2032
- 5.3 Global Antivirals Revenue by Region: 2021-2032
- 5.3.1 Global Antivirals Revenue by Region: 2021-2026
- 5.3.2 Global Antivirals Revenue by Region: 2027-2032
- 5.4 North America Antivirals Market Facts & Figures by Country
- 5.4.1 North America Antivirals Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Antivirals Sales by Country (2021-2032)
- 5.4.3 North America Antivirals Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Antivirals Market Facts & Figures by Country
- 5.5.1 Europe Antivirals Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Antivirals Sales by Country (2021-2032)
- 5.5.3 Europe Antivirals Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Antivirals Market Facts & Figures by Country
- 5.6.1 Asia Pacific Antivirals Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Antivirals Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Antivirals Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Antivirals Market Facts & Figures by Country
- 5.7.1 South America Antivirals Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Antivirals Sales by Country (2021-2032)
- 5.7.3 South America Antivirals Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Antivirals Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Antivirals Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Antivirals Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Antivirals Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Antivirals Sales by Type (2021-2032)
- 6.1.1 Global Antivirals Sales by Type (2021-2032) & (k tons)
- 6.1.2 Global Antivirals Sales Market Share by Type (2021-2032)
- 6.2 Global Antivirals Revenue by Type (2021-2032)
- 6.2.1 Global Antivirals Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Antivirals Revenue Market Share by Type (2021-2032)
- 6.3 Global Antivirals Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Antivirals Sales by Application (2021-2032)
- 7.1.1 Global Antivirals Sales by Application (2021-2032) & (k tons)
- 7.1.2 Global Antivirals Sales Market Share by Application (2021-2032)
- 7.2 Global Antivirals Revenue by Application (2021-2032)
- 7.2.1 Global Antivirals Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Antivirals Revenue Market Share by Application (2021-2032)
- 7.3 Global Antivirals Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Antivirals Value Chain Analysis
- 8.1.1 Antivirals Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Antivirals Production Mode & Process
- 8.2 Antivirals Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Antivirals Distributors
- 8.2.3 Antivirals Customers
9 Global Antivirals Analyzing Market Dynamics
- 9.1 Antivirals Industry Trends
- 9.2 Antivirals Industry Drivers
- 9.3 Antivirals Industry Opportunities and Challenges
- 9.4 Antivirals Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst